Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Bullish +65

We're lifting our price target on Cardinal Health after issuing rosy profit guidance

AI-generated analysis

📈 Cardinal Health raised its price target to $265 from $245 following a strong earnings beat in adjusted EPS of $2.60 versus the $2.42 consensus.

💰 The company delivered robust full-year guidance for fiscal 2027, projecting 13% to 15% adjusted earnings growth well ahead of Wall Street expectations.

📉 Q2 revenue of $63.67 billion missed estimates due to lower drug prices from Medicare negotiations and regulatory changes under the Inflation Reduction Act.

🚀 The 'Other' segment emerged as a high-growth engine with 11% to 13% projected revenue growth and a superior 10.6% segment profit margin.

💊 Cardinal Health is expanding into specialty pharmaceuticals and direct-to-patient delivery, including recent acquisitions to bolster its at-home solutions business.

📉 Free cash flow is expected to reach between $3.5 billion and $4 billion for fiscal 2027, exceeding the consensus estimate of $3.49 billion.

🏥 The Pharmaceutical and Specialty Solutions segment maintained strong profitability despite revenue headwinds from price caps on branded drugs.

📈 Shares of Cardinal Health rose more than 1% to set a fresh record close, reaching near its all-time high of $239.71.

🤝 CEO Jason Hollar affirmed the company's essential role in drug distribution, stating that compensation should not change despite lower wholesale costs.

📊 The 'Other' segment includes Nuclear and Precision Health Solutions and OptiFreight Logistics, driving fast top-line growth with high profitability.

Bullish Signals
  • Cardinal Health raised its price target to $265 from $245 after issuing rosy profit guidance for fiscal 2027 that significantly beat analyst expectations.
  • The company delivered an adjusted EPS of $2.60, surpassing the $2.42 consensus estimate, driven by strong execution and increased operating efficiency.
  • Cardinal Health is guiding for 13% to 15% adjusted earnings growth in fiscal 2027, well ahead of the Street's $12.04 per share expectation.
  • The 'Other' segment is the fastest-growing unit with projected revenue increases of 11% to 13% and a high 10.6% segment profit margin.
  • Free cash flow is expected to be between $3.5 billion and $4 billion for fiscal 2027, exceeding the FactSet consensus estimate of $3.49 billion.
  • The Pharmaceutical and Specialty Solutions segment generated better-than-expected profits despite revenue headwinds from regulatory price caps on drugs.
  • Cardinal Health is successfully pivoting into high-margin areas like specialty pharmaceuticals and direct-to-patient delivery of healthcare supplies.
  • Shares of Cardinal Health rose more than 1% to set a fresh record close, demonstrating strong investor confidence in the company's profitability.
Risk Factors
  • Q2 revenue of $63.67 billion missed expectations of $65.03 billion due to lower drug prices resulting from Medicare negotiations and regulatory changes.
  • The 'Other' segment revenue of $1.72 billion was slightly short versus Wall Street expectations, though it remains the fastest-growing unit.
  • Future profits in the Pharmaceutical segment could be impacted as contracts come up for renegotiation under lower wholesale acquisition costs.
Full Analysis
Cardinal Health (CAH) reported robust full-year earnings guidance for fiscal 2027 that exceeded analyst expectations, prompting an upgrade in its price target. While Q2 revenue of $63.67 billion missed the $65.03 billion consensus due to regulatory headwinds and lower drug prices, adjusted EPS of $2.60 beat estimates at $2.42. The company's stock rallied over 1% to set a fresh record close, trading near its all-time high despite some profit-taking after hitting intraday peaks. Analysts highlighted Cardinal Health's enhanced profitability as the firm successfully pivots toward high-margin areas like specialty pharmaceuticals and direct-to-patient delivery. The core Pharmaceutical and Specialty Solutions segment demonstrated strong execution, leveraging a volume-based fee-for-service model to generate superior profits even as Medicare negotiations capped wholesale drug prices. This operational efficiency allowed the company to deliver materially better-than-expected bottom-line results despite top-line pressure. Looking ahead, Cardinal Health is guiding for 13% to 15% adjusted earnings growth in fiscal 2027, significantly outpacing the Street's $12.04 per share expectation. The 'Other' segment continues to be a key growth driver with double-digit revenue expansion and high profit margins, while free cash flow is projected between $3.5 billion and $4 billion. Consequently, analysts raised their price target to $265 from $245 while maintaining a hold-equivalent rating. Management emphasized that the company's role in safely delivering life-saving products remains unchanged despite lower wholesale acquisition costs, arguing that compensation should reflect this enduring value. The strategy involves expanding managed services organizations and acquiring businesses to bolster direct-to-patient capabilities, diversifying revenue streams beyond traditional drug distribution. These strategic moves are expected to sustain long-term earnings growth and provide investors with exposure to high-margin healthcare innovations.